262 related articles for article (PubMed ID: 18427047)
1. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
Saito W; Kase S; Ohgami K; Mori S; Ohno S
Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
[TBL] [Abstract][Full Text] [Related]
4. [Intraocular bevacizumab as palliative therapy in melanoma-metastasis-associated rubeotic secondary glaucoma].
Jaissle GB; Ulmer A; Henke-Fahle S; Aisenbrey S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
Klin Monbl Augenheilkd; 2009 Jan; 226(1):70-2. PubMed ID: 19173168
[No Abstract] [Full Text] [Related]
5. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.
Barkmeier AJ; Akduman L
Ocul Immunol Inflamm; 2009; 17(2):109-17. PubMed ID: 19412873
[TBL] [Abstract][Full Text] [Related]
7. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
Beer PM; Wong SJ; Hammad AM; Falk NS; O'Malley MR; Khan S
Retina; 2006 Oct; 26(8):871-6. PubMed ID: 17031285
[TBL] [Abstract][Full Text] [Related]
8. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
[TBL] [Abstract][Full Text] [Related]
10. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study.
Patwardhan SD; Azad R; Shah BM; Sharma Y
Retina; 2011 May; 31(5):866-70. PubMed ID: 21301382
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab (Avastin) for the treatment of neovascular glaucoma.
Chilov MN; Grigg JR; Playfair TJ
Clin Exp Ophthalmol; 2007 Jul; 35(5):494-6. PubMed ID: 17651259
[TBL] [Abstract][Full Text] [Related]
14. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Mason JO; Albert MA; Mays A; Vail R
Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
[No Abstract] [Full Text] [Related]
15. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
dell'Omo R; Kulkarni A; Franks WA
Acta Ophthalmol; 2008 Sep; 86(6):698-700. PubMed ID: 18081905
[No Abstract] [Full Text] [Related]
16. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
Yeung SN; Paton KE; Waite C; Maberley DA
Can J Ophthalmol; 2010 Jun; 45(3):269-73. PubMed ID: 20379286
[TBL] [Abstract][Full Text] [Related]
17. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
Gallagher DC; Bhatt RS; Parikh SM; Patel P; Seery V; McDermott DF; Atkins MB; Sukhatme VP
Clin Cancer Res; 2007 Apr; 13(7):2115-20. PubMed ID: 17404094
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma.
Terheyden P; Hofmann MA; Weininger M; Bröcker EB; Becker JC
J Cancer Res Clin Oncol; 2007 Nov; 133(11):897-901. PubMed ID: 17583821
[TBL] [Abstract][Full Text] [Related]
19. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
20. Vitreous web after pars plana vitrectomy and bevacizumab with fluid-air exchange.
Chiang A; Reddy S; Tsui I; Hubschman JP
Semin Ophthalmol; 2011 Jan; 26(1):25-7. PubMed ID: 21275601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
